Conditions of Growth, Economic Analysis - Research Report on Questcor Pharmaceuticals, Inc. and Dendreon Corporation

Marketwired

HONG KONG--(Marketwire -02/27/12)- Today, www.EquityLeader.com introduced research coverage of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR - News) and Dendreon Corporation (NASDAQ: DNDN - News). Full research reports are available to readers at: www.EquityLeader.com/index.php?sm1=QCOR&sm2=DNDN.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Equity Leader has decided to cover Questcor Pharmaceuticals, Inc. for its current position within the healthcare industry. Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. Questcor primary product is H.P. Acthar Gel (repository corticotropin injection) (Acthar), an injectable drug that is approved by the United States Food and Drug Administration (FDA). Acthar is approved for the treatment of 19 indications. A copy of this report detailing Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR - News) is available at: www.EquityLeader.com/index.php?sm1=QCOR.

Equity Leader is also taking note of Dendreon Corporation for its changing role within the healthcare industry. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. To download free research on Dendreon Corporation (NASDAQ: DNDN - News) investors may visit: www.EquityLeader.com/index.php?sm2=DNDN.

About Equity Leader
Whether you are a first time investor or seasoned market professional, Equity Leader provides the resources necessary to simplify your research process. Our focus has always been to empower investors with the information they need to make their own investment decisions.

Contact:
View Comments (0)